Fuji Pharma Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fuji Pharma Co. Ltd.
Japan's national health insurance scheme will reimburse infertility treatments from April 2022, in a bid to make the treatments more accessible to patients by effectively lowering the cost by 70%. The key strategic aim is to raise a low birth rate and the move is also set to substantially expand the market for such products for both domestic and foreign players.
Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.
Longtime partners Alvotech and Fuji Pharma – the latter being a minority shareholder in the Icelandic firm – have extended their existing biosimilars partnership in Japan, as Alvotech continues to make strategic moves across the globe.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools